Olon USA will be exhibiting at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois, from April 25th to April 30th. The event serves as a global platform for leading scientists and industry professionals to showcase the latest advancements in cancer research. This marks Olon USA’s first participation in the conference, reflecting its strategic move into the oncology market with high-potency API development capabilities.
Advancing Cancer Research with High-Potency Capabilities
Olon USA has expanded its capabilities to support cancer research and the development of small molecules for oncology treatments. The company’s advanced high-potency API suite is designed to handle complex challenges in drug development, ensuring safe and efficient production of highly potent active pharmaceutical ingredients (HPAPIs). With its OEB 5-rated containment system, Olon USA can effectively manage occupational exposure while maintaining stringent safety protocols.
With extensive experience in clinical trial manufacturing for oncology drugs, Olon USA is positioned to collaborate with researchers and pharmaceutical companies developing the next generation of cancer treatments. By leveraging cutting-edge containment technologies and scalable production capabilities, Olon USA offers a seamless transition from early-stage development to commercial manufacturing.
Connecting with the Scientific Community
The AACR Annual Meeting provides an opportunity for Olon USA to engage directly with cancer researchers, pharmaceutical developers, and industry professionals. The company will have a dedicated presence at Booth #4446, where both business development professionals and scientists will be available to discuss Olon USA’s expertise in both high-potency manufacturing and oncology drug development.
In addition to booth discussions, Olon USA scientists will be attending poster sessions to explore emerging oncology molecules and potential collaboration opportunities. These sessions serve as an ideal platform for in-depth scientific discussions, allowing researchers to gain insights into the latest breakthroughs and identify new opportunities for collaboration. Olon USA’s presence at these sessions underscores its commitment to fostering scientific innovation and advancing cancer research.
Seamless Transition from Early-Stage to Commercial Manufacturing
Olon USA’s expertise in handling highly potent compounds allows for seamless project transitions from early-stage development through clinical trials and into commercial manufacturing. The company’s ability to work with HPAPIs ensures that drug developers can scale their processes efficiently while maintaining compliance with industry regulations. If an oncology drug candidate remains highly potent beyond Phase III trials, Olon USA can evaluate the material for manufacture within the OUSA plant, or transfer production to one of its larger global sites with high-potency capabilities, ensuring scalability and regulatory compliance.
By integrating advanced containment strategies and specialized equipment, Olon USA mitigates risks associated with handling highly potent compounds, making it a reliable partner for oncology drug development. The company’s expertise extends beyond manufacturing, providing strategic guidance on formulation, process optimization, and regulatory pathways to accelerate the journey from research to market.
Meet Olon USA at the AACR Annual Meeting
Olon USA encourages researchers, pharmaceutical developers, and industry professionals to schedule meetings in advance to discuss their projects and explore collaboration opportunities. Connect with the Olon USA team at AACR 2025 to learn more about how its specialized capabilities in high-potency API development can support oncology research and drug manufacturing. Contact the team today to start a conversation about your next breakthrough in cancer treatment.